Dear Women's Imaging Insider,
One benefit of molecular breast imaging is that it can help doctors identify tumor margins before surgery, potentially decreasing the number of second surgeries women have to undergo to remove residual disease. But which modality is most helpful?
Researchers at the American College of Radiology Imaging Network compared a few molecular breast imaging modalities -- positron emission mammography, whole-body PET, and whole-body PET/CT -- to determine which performed best in index and additional cancer detection, presurgical planning, and axillary staging.
Click here to read what they found. As an Insider subscriber, you get access to the article before our other members.
Once you've read our feature, take a look at what else is going on in the Women's Imaging Digital Community:
- Discover what Harvard radiologists have to say about women's quality of life and uterine fibroid treatment.
- Read how high-volume radiologists produce fewer false-positive mammograms.
- Find out why mammography screening is less effective in women with cancer histories.
- Get the scoop on why French researchers suggest that breast screening may not lead to mortality decreases.
- Learn how breast MRI screening benefits women with a history of radiation therapy.
As always, if you have a comment, report, or article idea to share about any aspect of women's imaging, I invite you to contact me.
